Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting natural killer cells and natural killer T cells in cancer.

Literature DB >> 22437937

Targeting natural killer cells and natural killer T cells in cancer.

Eric Vivier¹, Sophie Ugolini, Didier Blaise, Christian Chabannon, Laurent Brossay.

Abstract

Natural killer (NK) cells and natural killer T (NKT) cells are subsets of lymphocytes that share some phenotypical and functional similarities. Both cell types can rapidly respond to the presence of tumour cells and participate in antitumour immune responses. This has prompted interest in the development of innovative cancer therapies that are based on the manipulation of NK and NKT cells. Recent studies have highlighted how the immune reactivity of NK and NKT cells is shaped by the environment in which they develop. The rational use of these cells in cancer immunotherapies awaits a better understanding of their effector functions, migratory patterns and survival properties in humans.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Year: 2012 PMID： 22437937 PMCID： PMC5161343 DOI： 10.1038/nri3174

Source DB: PubMed Journal: Nat Rev Immunol ISSN： 1474-1733 Impact factor: 53.106

231 in total

Review 1. Bone-marrow transplantation (first of two parts).

Authors: E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal: N Engl J Med Date: 1975-04-17 Impact factor: 91.245

2. Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance.

Authors: Sophie Guia; Baptiste N Jaeger; Stefan Piatek; Sébastien Mailfert; Tomasz Trombik; Aurore Fenis; Nicolas Chevrier; Thierry Walzer; Yann M Kerdiles; Didier Marguet; Eric Vivier; Sophie Ugolini
Journal: Sci Signal Date: 2011-04-05 Impact factor: 8.192

3. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders.

Authors: C Chen; M Busson; V Rocha; M-L Appert; V Lepage; N Dulphy; P Haas; G Socié; A Toubert; D Charron; P Loiseau
Journal: Bone Marrow Transplant Date: 2006-08-07 Impact factor: 5.483

4. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.

Authors: Shinichiro Motohashi; Aki Ishikawa; Eiichi Ishikawa; Mizuto Otsuji; Toshihiko Iizasa; Hideki Hanaoka; Naomi Shimizu; Shigetoshi Horiguchi; Yoshitaka Okamoto; Shin-ichiro Fujii; Masaru Taniguchi; Takehiko Fujisawa; Toshinori Nakayama
Journal: Clin Cancer Res Date: 2006-10-06 Impact factor: 12.531

5. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors: P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal: N Engl J Med Date: 1979-05-10 Impact factor: 91.245

6. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation.

Authors: Mark Cook; David Briggs; Charles Craddock; Premini Mahendra; Donald Milligan; Christopher Fegan; Philip Darbyshire; Sarah Lawson; Elizabeth Boxall; Paul Moss
Journal: Blood Date: 2005-10-20 Impact factor: 22.113

Review 7. Oncogenic stress sensed by the immune system: role of natural killer cell receptors.

Authors: David H Raulet; Nadia Guerra
Journal: Nat Rev Immunol Date: 2009-08 Impact factor: 53.106

8. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses.

Authors: Silke Paust; Harvinder S Gill; Bao-Zhong Wang; Michael P Flynn; E Ashley Moseman; Balimkiz Senman; Marian Szczepanik; Amalio Telenti; Philip W Askenase; Richard W Compans; Ulrich H von Andrian
Journal: Nat Immunol Date: 2010-10-24 Impact factor: 25.606

9. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.

Authors: Claudia Brehm; Sabine Huenecke; Andrea Quaiser; Ruth Esser; Melanie Bremm; Stephan Kloess; Jan Soerensen; Hermann Kreyenberg; Christian Seidl; Petra S A Becker; Heiko Mühl; Thomas Klingebiel; Peter Bader; Jakob R Passweg; Dirk Schwabe; Ulrike Koehl
Journal: PLoS One Date: 2011-11-09 Impact factor: 3.240

10. Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation.

Authors: Jin S Im; Pooja Arora; Gabriel Bricard; Alberto Molano; Manjunatha M Venkataswamy; Ian Baine; Elliot S Jerud; Michael F Goldberg; Andres Baena; Karl O A Yu; Rachel M Ndonye; Amy R Howell; Weiming Yuan; Peter Cresswell; Young-Tae Chang; Petr A Illarionov; Gurdyal S Besra; Steven A Porcelli
Journal: Immunity Date: 2009-06-19 Impact factor: 31.745

309 in total

1. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Authors: Joe-Marc Chauvin; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Richelle DeBlasio; Cindy Sanders; Jiajie Hou; Xian-Yang Li; Soldano Ferrone; Diwakar Davar; John M Kirkwood; Robert J Johnston; Alan J Korman; Mark J Smyth; Hassane M Zarour
Journal: Clin Cancer Res Date: 2020-06-26 Impact factor: 12.531

Review 2. Turned on by danger: activation of CD1d-restricted invariant natural killer T cells.

Authors: Victoria Lawson
Journal: Immunology Date: 2012-09 Impact factor: 7.397

3. Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.

Authors: Armando M Marrufo; Stephen O Mathew; Pankaj Chaudhary; Joseph D Malaer; Jamboor K Vishwanatha; Porunelloor A Mathew
Journal: Am J Cancer Res Date: 2018-06-01 Impact factor: 6.166

Targeting natural killer cells and natural killer T cells in cancer.

Review 1. Bone-marrow transplantation (first of two parts).

2. Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance.

3. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders.

4. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.

5. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

6. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation.

Review 7. Oncogenic stress sensed by the immune system: role of natural killer cell receptors.

8. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses.

9. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.

10. Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation.

1. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Review 2. Turned on by danger: activation of CD1d-restricted invariant natural killer T cells.

3. Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.

Review 4. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Review 5. Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Review 6. Inflammation-on-a-Chip: Probing the Immune System Ex Vivo.

Review 7. SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Review 8. Commensal microbiota and NKT cells in the control of inflammatory diseases at mucosal surfaces.

9. Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity.

10. The Stalk Domain of NKp30 Contributes to Ligand Binding and Signaling of a Preassembled NKp30-CD3ζ Complex.